News
OTLK
0.5750
+0.26%
0.0015
Outlook submits HCPCS Level II application to CMS for J-code for LYTENAVA
TipRanks · 9h ago
Outlook Therapeutics Files Application With Centers For Medicare & Medicaid Services Seeking Healthcare Common Procedure Coding System Level II J-Code For LYTENAVA To Treat Macular Degeneration
Benzinga · 9h ago
Outlook Therapeutics Faces Nasdaq Minimum Bid Price Deficiency
TipRanks · 1d ago
Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 156%
Barron‘s · 3d ago
Kodiak Sciences Stock Surges 102% After Eye-Disease Drugs Pass Key Trial
Barron‘s · 3d ago
Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial
Barron‘s · 3d ago
Weekly Report: what happened at OTLK last week (0921-0925)?
Weekly Report · 3d ago
Weekly Report: what happened at OTLK last week (0914-0918)?
Weekly Report · 09/21 09:47
Outlook Therapeutics Sets U.S. Price for LYTENAVA
TipRanks · 09/18 21:20
Weekly Report: what happened at OTLK last week (0907-0911)?
Weekly Report · 09/14 09:50
Outlook Therapeutics Is Maintained at Buy by Ascendiant Capital
Dow Jones · 09/11 10:14
Outlook Therapeutics Price Target Raised to $10.50/Share From $10.00 by Ascendiant Capital
Dow Jones · 09/11 10:14
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
Benzinga · 09/11 10:04
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
Barchart · 09/11 06:00
Outlook Therapeutics Highlights LYTENAVA FDA Approval And U.S. Commercial Opportunity
NASDAQ · 09/10 14:39
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Barchart · 09/10 08:10
Weekly Report: what happened at OTLK last week (0831-0904)?
Weekly Report · 09/07 09:46
Weekly Report: what happened at OTLK last week (0824-0828)?
Weekly Report · 08/31 09:51
Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories
NASDAQ · 08/29 10:34
Outlook Therapeutics Appoints Kevin Lundquist As CFO Ahead Of U.S. LYTENAVA Launch; Stock Up
NASDAQ · 08/28 06:05
More
Webull provides a variety of real-time OTLK stock news. You can receive the latest news about Outlook Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLK
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.